RxDoctor Payments Data

Laurie Lerner, MD

Pulmonary Disease · Rochester, NYNPI 1316045313

Payments from drug & device makers

$2,897in general payments, 2019–2025

Across 149 payments — averaging $19.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$882
  • AstraZeneca$526
  • Boehringer Ingelheim$248
  • Amgen$144
  • Insmed, Inc.$137
  • Grifols USA, LLC$134
  • plus $826 from 14 others

What the payments were for

  • Food & beverage$2,897100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,897 in reported general payments places this provider in the 60th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$147,640
Medicare patients
561
Services billed
1,241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter145$142,211
Prolastin CAlpha-1-Proteinase Inhibitor13$115,762
Fasenra PenBenralizumab15$83,522
Breztri AerosphereBudesonide/Glycopyr/Formoterol106$82,516
TezspireTezepelumab-Ekko14$61,480
Dupixent SyringeDupilumab14$53,329
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr56$42,439
NucalaMepolizumab11$38,560
Breo ElliptaFluticasone/Vilanterol57$35,476
SymbicortBudesonide/Formoterol Fumarate71$20,142
Spiriva RespimatTiotropium Bromide19$18,825
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate42$13,687
Fluticasone-SalmeterolFluticasone Propion/Salmeterol48$9,447
Incruse ElliptaUmeclidinium Bromide20$6,565
Varenicline Tartrate19$4,861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Breo Ellipta, Incruse Ellipta$882$265,251289 claims
AstraZenecaBreztri Aerosphere, Tezspire, Symbicort$526$164,138191 claims
Grifols USA, LLCProlastin C$134$115,76213 claims
Boehringer IngelheimSpiriva Respimat$248$18,82519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →